Patient

Patients

Education & Access

  • Find a Theranostic Clinical Trial Right for You!
  • Ability to Contact Expert Theranostic Oncologists
  • Education to better understand Radiation
  • Education to better understand Theranostics
  • Education to better understand Clinical Trials

Along with specific trial information. TheranosticTrials.org contains much easy-to-understand background information on what is Theranostics, what is radiation, and dispelling many of the myths and misconceptions of clinical trials.

Search for Trials by Cancer Type


DI Badge

Distinguished Investigator

A Distinguished Investigator of Theranostics is a level of distinction conferred upon an individual physician who has demonstrated a mastery of conducting novel radioligand therapies and molecular imaging clinical trials.

Michael Gorin, MD

Dr. Michael Gorin is an associate professor of urology at the Icahn School of Medicine at Mount Sinai. Dr. Gorin is widely recognized for his work studying the use of molecular imaging in the diagnosis and management of urologic malignancies. To his credit, Dr. Gorin was part of the first clinical team to study PSMA-targeted PET imaging of prostate cancer with PYLARIFY (18F-DCFPyL). Additionally, he played an integral role in the design and conduct of two multicenter clinical trials that led to the approval of this novel PET radiotracer by the United States Food and Drug Administration. Since its approval in May 2021, PYLARIFY has been used to image over 100,000 men with prostate cancer. Dr. Gorin has also made significant contributions to the field of urology through his research on prostate cancer screening, active surveillance, and focal therapy. More recently, Dr. Gorin’s academic focus has shifted towards the implementation of artificial intelligence tools to improve the care of urologic patients. This work includes developing computer vision tools to augment the diagnostic capabilities of existing radiology techniques. Additionally, he has developed expertise working with voice and text-based large language models. He has developed a variety of applications aimed at improving medical education, patient care, and physician efficiency. To date, Dr. Gorin has published over 300 scholarly articles in the medical literature. Additionally, he has contributed to multiple medical textbooks, including chapters in Campbell-Walsh-Wein Urology, The 5-Minute Urology Consult, and Gray's Anatomy. In July 2022, Dr. Gorin was named Editor-in-Chief of BJUI Compass, the open-access companion journal to the British Journal of Urology International. Dr. Gorin also serves on the editorial boards of several other journals including Urologic Oncology and the World Journal of Urology. Dr. Gorin has received numerous honors and awards for his scholarly work, including the Drs. Carl and Barbara Alving Endowed Award for Outstanding Biomedical Research from the University of Miami Miller School of Medicine and the William F. Rienhoff, Jr., M.D. Scholar Award from Johns Hopkins University School of Medicine. Dr. Gorin attended college at the University of Michigan, earning a Bachelor of Science in Cellular and Molecular Biology. He then attended medical school at the University of Miami Leonard M. Miller School of Medicine, where he graduated as an inductee to the Alpha Omega Alpha Honor Medical Society. Following medical school, Dr. Gorin completed a general surgery internship, urology residency, and fellowship in endoscopic and minimally invasive urology at the world-renowned James Buchanan Brady Urological Institute at Johns Hopkins University School of Medicine

Read More >>

See All Investigators

About Us

TheranosticTrials was developed through the collaboration of 2 key opinion leaders in the field of Radiopharmaceuticals. Drs. Luke Nordquist and Oliver Sartor saw the need for a such a web-based tool to provide patient education & ultimately improve access to the rapidly expanding field of radiopharmaceutical clinical trials. Patients globally are seeking access to these highly sought-after clinical trials which are providing new hope.


Education


banana

RLT Components

RADIOLIGAND THERAPY (RLT) is a highly effective approach to very accurately locating cancer cells and effectively killing those same cells by delivery various radioisotopes to a specific target that is located on a type of cancer. Some of the Radioisotopes are diagnostic for locating cancers & some therapeutic to treat the cancers.

There are several Components to a RLT that are simply demonstrated in the truck diagram including:

  1. Cancer Targets
  2. Ligand (demonstrated as the Truck GPS set to find a specific Target)
  3. Diagnostic Radioisotopes (demonstrated as light bulbs that light the cancer Targets on a PET scan)
  4. Therapeutic Radioisotopes (demonstrated as bombs that kill cancer cells that express the target with either Alpha or Beta radiation)
  5. Linker (demonstrated as the hitch keeping the Radioisotope attached to the Ligand)
  6. Chelator (demonstrated as the Trailers which keeps the Radioisotope on Target).

To learn more about the specific components being studied today on clinical trials around the world check out the RLT COMPONENTS Tab.

View RLT Components

Stats

Theranostic Trials Global Ecosystem

View All

Loading...
Loading...

Get To know Radiation

Radiation is naturally occurring and unavoidable in our day-to-day living

Let’s compare Bananas!

banana

Sponsors

Loading...